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Abstract
Background: Extracorporeal carbon dioxide removal is an increasingly used respiratory support technique. As is
true of all extracorporeal techniques, extracorporeal carbon dioxide removal needs proper anticoagulation. We
report a case of a patient at risk of bleeding complications who was treated with extracorporeal carbon dioxide
removal and anticoagulated with a regional technique.
Case presentation: A 56-year-old Caucasian man with a history of chronic obstructive pulmonary disease
exacerbation required extracorporeal carbon dioxide removal for severe hypercapnia and acidosis despite
mechanical ventilation. The extracorporeal circuit was anticoagulated using a regional heparin technique to
limit the patient’s risk of bleeding due to a low platelet count. The patient underwent 96 h of effective
extracorporeal carbon dioxide removal without any adverse events. He was successfully weaned from
extracorporeal carbon dioxide removal. During the treatment, no bleeding complications or unexpected circuit
clotting was observed.
Conclusions: The use of regional heparin anticoagulation technique seems to be feasible and safe during
extracorporeal carbon dioxide removal.
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Background
Extracorporeal carbon dioxide (CO2) removal (ECCO2r) is
a technique that allows artificial respiratory support by
providing CO2 clearance through an extracorporeal
circuit, thus unloading the respiratory system. ECCO2r
has been used during acute respiratory distress syndrome
(ARDS) to allow protective ventilation without increasing
partial pressure of carbon dioxide (PaCO2) [1]. Other indi-
cations include chronic obstructive pulmonary disease
(COPD) exacerbation and refractory respiratory acidosis
[1]. Because blood has to proceed through an extracor-
poreal circuit and filters, proper anticoagulation is needed.
The best anticoagulation strategy for ECCO2r is still
debated [2, 3]. We present a case of a patient with
COPD with acute respiratory failure who was treated in
an intensive care unit (ICU) with ECCO2r support using
a regional heparin anticoagulation method.
Case presentation
Our patient was a 56-year-old Caucasian married man
with height 172 cm, weight 75 kg, and body mass index
25.4 kg/m2. He was admitted to our emergency depart-
ment for severe dyspnea and desaturation.
The patient had a history of heavy smoking (30 pack-
years) and no alcohol intake. In the last year, he had had
two hospitalizations for acute exacerbation of COPD
and was classified as Global Initiative for Chronic
Obstructive Lung Disease class C. He was admitted to
the ICU and eventually was tracheostomized. After his
ICU stay, he was decannulated and actually showed a
former closed tracheal stoma. Moreover, he had type 2
diabetes mellitus and hypertension, and he presented
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with a former closed tracheal stoma after his last ICU
admission for COPD exacerbation. His medication history
included ramipril, pantoprazole, and inhalation inda-
catarol/glycopyrronium.
At arrival, the patient showed hypercapnic respiratory
acidosis (pH 7.24, partial pressure of oxygen 45mmHg,
PaCO2 70mmHg, HCO3
− 32mEq/L). Standard medical
therapy and noninvasive ventilation (NIV) were imme-
diately started. The result of his neurological examination
was normal with a Glasgow Coma Scale score of 15. His
heart rate was 106 beats/min, peripheral oxygen saturation
was 86%, noninvasive blood pressure was 135/85mmHg,
and body temperature was 37.8 °C. A chest computed
tomographic scan showed a centrilobular emphysema and
a bilateral fibrothorax (Fig. 1).
A few hours after admission, the patient was intubated
for worsening mental status and worsening respiratory
acidosis (pH 7.18, PaCO2 85 mmHg). Mechanical venti-
lation in pressure support mode was started in the ICU
associated with salmeterol and fluticasone 50 μg/100 μg
inhalational therapy every 8 h. Sedation was obtained by
titrating propofol infusion to obtain a Richmond
Agitation-Sedation Scale score of − 1. On the basis of
white blood cell count of 22 × 109/L, high procalcitonin
serum level 12 ng/ml, and strong suspicion of a pulmo-
nary infection, bronchoalveolar lavage was collected, and
intravenous broad-spectrum empiric antibiotic therapy
with piperacillin-tazobactam 4.5 g every 8 h and vanco-
mycin 500mg every 6 h was started. After 72 h, qualita-
tive bronchial cultures showed a negative Gram stain
and heavy growth of Pseudomonas aeruginosa. At this
point, intravenous cefepime 2 g every 8 h was started.
On day 4 after admission, owing to the severity of lung
infection, hypercapnic respiratory acidosis worsened to
pH 6.98 and PaCO2 157mmHg despite profound sedation
and the maximization of minute alveolar ventilation. A
low platelet count of 50,000 cells/μl was recorded. ECCO2r
was started through a 16-French dialysis bilumen catheter
inserted into the right femoral vein using continuous renal
replacement therapy (CRRT) (Diapact® system; B. Braun
Medical, Milan, Italy) with a Diacap Acute® filter (B. Braun
Medical). The extracorporeal circuit was regionally anticoa-
gulated with heparin administered prefilter and protamine
sulfate administered postfilter (Fig. 1).
Table 1 shows blood gas analyses before, during, and
after ECCO2r treatment. The patient’s PaCO2 dropped to
54mmHg and pH increased to 7.21 after 6 h of treatment.
The Diacap Acute® filter was replaced every 24 h during
ECCO2r. On day 6 after admission, because PaCO2 consis-
tently less than 60mmHg, ECCO2r weaning was attempted,
and the patient was switched again into pressure support
mode. ECCO2r was started again 2 h later because of a rise
in PaCO2. On day 7 after admission, the patient was suc-
cessfully weaned from ECCO2r. Under pressure support
ventilation, he was able to maintain an acceptable PaCO2
level (59mmHg). On day 9 after admission, the patient be-
came febrile with associated hypotension and increased
serum lactate level. Multiple organ failure developed during
the following 48 h. On day 11 after admission, blood cul-
tures evidenced multidrug-resistant P. aeruginosa.
Extracorporeal circuit and anticoagulation technique
The extracorporeal circuit was primed two times, first
with 1 L of NaCl 0.9% + 10,000 IU of unfractionated
heparin and then with 1 L of NaCl 0.9%. A 500-IU/ml
heparin solution was prepared and infused prefilter at
0.15 IU/ml/h of blood flow (Fig. 2). A protamine con-
centration of 5 mg/ml was infused to match the heparin
infusion rate [4]. ECCO2r was started at a blood flow of
300 ml/min and increased slowly to 450 ml/min to
maximize CO2 removal.
Discussion
To the best of our knowledge, this case report is the first in
the literature of regionally anticoagulated ECCO2r in a pa-
tient with COPD with acute respiratory failure. The main
finding in this case report is the efficacy and safety of using
ECCO2r with a heparin regional anticoagulation regimen.
Severe hypercapnia has several detrimental pathophysio-
logical effects. Accumulation of CO2 causes acidosis,
reduced consciousness, and an increase in cerebral blood
flow due to vasodilation. Moreover, hypercapnic acidosis
causes myocardial depression and pulmonary vasocon-
striction, raising the risk of both right and left ventricular
failure [5].
First conceived in the late 1970s, ECCO2r has been
used as an adjuvant respiratory treatment for patients
with severe ARDS ventilated with protective ventilation
but in need of increasing CO2 elimination [6] and
Fig. 1 Chest computed tomography performed on day 1 showing
diffused centrilobular emphysema and a fibrothorax aspect. Air
bronchograms were evidenced bilaterally at bases
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reducing tidal volumes to limit lung damage. More re-
cently, ECCO2r has been used for the treatment of severe
COPD exacerbations to avoid intubation [7] or in weaning
from mechanical ventilation and as a supportive treatment
of severe respiratory hypercapnic acidosis [8].
Our patient had an acute COPD exacerbation for
which NIV treatment failed in the emergency depart-
ment. Mechanical ventilation in the ICU was challenging
because of the patient’s obstructive restrictive pattern.
Minute ventilation was increased to 13 L/min, reaching
safe pressure limits (driving pressure < 15 cm H2O).
However, acceptable pH and CO2 levels were not ob-
tained. Because standard medical treatment and mech-
anical ventilation were unsuccessful, ECCO2r was
started to improve the life-threatening hypercapnic acid-
osis and potentially injurious mechanical ventilation.
As is true of most continuous venovenous blood purifi-
cation systems, ECCO2r needs anticoagulation to ensure
circuit and filter patency. The best anticoagulation strategy
is still debated in the literature. A recent systematic review
that summarized the evidence about anticoagulation du-
ring CRRT indicated that regional citrate-based anticoagu-
lation was the most efficient and safe method [2].
However, the citrate-based anticoagulation regimen can
induce hypocalcemia and metabolic alkalosis. Moreover,
in order to reach efficacious venovenous ECCO2r, a mini-
mum blood flow of 350ml/min is necessary. Therefore,
citrate could hardly be the anticoagulation mode of choice
because of the excessive fluid volume and metabolic load
for the body. Indeed, the amount of infused citrate could
be above the hepatic metabolic limit, thus resulting in
citrate intoxication. Last, postfilter calcium administration
Table 1 Blood gas analyses before, during, and after extracorporeal carbon dioxide removal with regional anticoagulation
Blood gas analyses
ED ICU
Day 1 Day 1 Day 2 Day 3 Day 4 Day 5 Day 6 Day 7 Day 8 Day 9 Day 10
pH 7.24 7.18 7.19 7.12 6.99 7.28 7.30 7.31 7.30 7.28 7.22
PaO2 70 90 84 125 101 99 140 119 111 132 143
PaCO2 129 114 142 123 157 61 56 55 58 56 55
Post ECCO2r Filter change Weaning trial Weaning trial
pH 7.29 7.31 7.24 7.30
PaO2 145 108 129 113
PaCO2 54 52 73 59
ECCO2r was started at day 4
Abbreviations: ECCO2r extracorporeal carbon dioxide removal, ED Emergency department, ICU Intensive care unit, PaCO2 Partial pressure of carbon dioxide, PaO2
Partial pressure of oxygen
Fig. 2 Schematic representation of extracorporeal carbon dioxide removal with regional heparin protamine anticoagulation. PA Arterial pressure,
PBE Prefilter pressure, PV Venous pressure, SAD Safety air detector, SAC Safety clamp
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could require a massive dosage and a very high speed of
infusion to correct the citrate-related hypocalcemia [9].
Potential hemorrhage was a major concern in our patient
because of low platelet count. Thus, in our opinion,
regional anticoagulation with heparin and protamine was
the best regimen to reduce bleeding risk. Regional
heparin-based anticoagulation is widely used in CRRT
worldwide [4]. Nevertheless, in their randomized con-
trolled trial conducted in 2015, Gattas et al. compared re-
gional heparin with regional citrate for anticoagulation in
CRRT and concluded that an equivalent safety profile and
use of citrate allowed a longer CRRT filter life [10].
Regional heparin anticoagulation is not without risk.
Because heparin is supposed to have a longer half-life
than protamine, there is a risk of rebound bleeding in
cases of incorrect titration. Furthermore, this technique
exposes the patient to side effects caused by heparin,
such as thrombocytopenia, and to the risks of protamine
administration, such as anaphylaxis, hypotension, and
pulmonary vasoconstriction [11]. Nevertheless, most of
these drawbacks can be avoided with a slow protamine
infusion and a precise heparin-neutralizing protocol.
This case report has limitations. First, we did not per-
form viscoelastic tests (rotational thromboelastometry or
thromboelastography). Moreover, we did not evaluate
the heparin-protamine complexes in the patient’s blood,
so we do not know the serum half-life of the complexes.
However, we did not detect any major or minor bleeding
event. Daily platelet count and standard coagulation test
results were stable and within normal range throughout
the treatment.
Conclusions
With the increasing use of ECCO2r, there is a need to
increase its safety with regard to anticoagulation. Regional
heparin anticoagulation may represent a feasible way to
provide ECCO2r for CRRT. Adequately powered studies
are needed to confirm these observations.
Abbreviations
ARDS: Acute respiratory distress syndrome; CO2: Carbon dioxide;
COPD: Chronic obstructive pulmonary disease; CRRT: Continuous renal
replacement therapy; ECCO2r: Extracorporeal carbon dioxide removal;
ICU: Intensive care unit; NIV: Noninvasive ventilation; PaCO2: Partial pressure
of carbon dioxide; PaO2: Partial pressure of oxygen
Acknowledgements
Not applicable.
Funding
None.
Availability of data and materials
Not applicable.
Authors’ contributions
JT, AC, and CG conceived of the content and wrote the manuscript. FV, CP,
PI, FF, and AG reviewed and critically revised the manuscript. All authors read
and approved the final version of the manuscript.
Ethics approval and consent to participate
Not applicable.
Consent for publication
Written informed consent was obtained from the patient’s relatives for
publication of this case report and any accompanying images. A copy of the
written consent is available for review by the Editor-in-Chief of this journal.
Competing interests
The authors declare that they have no competing interests.
Publisher’s Note
Springer Nature remains neutral with regard to jurisdictional claims in
published maps and institutional affiliations.
Author details
1Department of Surgical, Oncological and Oral Science (Di.Chir.On.S.), Section
of Anesthesia, Analgesia, Intensive Care and Emergency, Policlinico Paolo
Giaccone, University of Palermo, Palermo, Italy. 2Department of Anesthesia
and Intensive Care, University of Palermo, Palermo, Italy. 3Department of
Anesthesia and Intensive Care, University of Pisa, Pisa, Italy.
Received: 3 December 2018 Accepted: 13 March 2019
References
1. Morelli A, Del Sorbo L, Pesenti A, Ranieri VM, Fan E. Extracorporeal carbon
dioxide removal (ECCO2R) in patients with acute respiratory failure. Intensive
Care Med. 2017;43:519–30.
2. Liu C, Mao Z, Kang H, Hu J, Zhou F. Regional citrate versus heparin
anticoagulation for continuous renal replacement therapy in critically ill
patients: a meta-analysis with trial sequential analysis of randomized
controlled trials. Crit Care. 2016;20:144.
3. Sharma AS, Weerwind PW, Bekers O, Wouters EM, Maessen JG. Carbon
dioxide dialysis in a swine model utilizing systemic and regional
anticoagulation. Intensive Care Med Exp. 2016;4:2.
4. RENAL Replacement Therapy Study Investigators. Intensity of continuous
renal-replacement therapy in critically ill patients. N Engl J Med. 2009;361:
1627–38.
5. Stengl M, Ledvinova L, Chvojka J, Benes J, Jarkovska D, Holas J, et al. Effects of
clinically relevant acute hypercapnic and metabolic acidosis on the
cardiovascular system: an experimental porcine study. Crit Care. 2013;17:R303.
6. Kolobow T, Gattinoni L, Tomlinson TA, Pierce JE. Control of breathing using
an extracorporeal membrane lung. Anesthesiology. 1977;46:138–41.
7. Sklar MC, Beloncle F, Katsios CM, Brochard L, Friedrich JO. Extracorporeal
carbon dioxide removal in patients with chronic obstructive pulmonary
disease: a systematic review. Intensive Care Med. 2015;41:1752–62.
8. Burki NK, Mani RK, Herth FJF, et al. A novel extracorporeal CO2 removal
system: results of a pilot study of hypercapnic respiratory failure in patients
with COPD. Chest. 2013;143(3):678–86.
9. Scaravilli V, Di Girolamo L, Scotti E, Busana M, Biancolilli O, Leonardi P, et al.
Effects of sodium citrate, citric acid and lactic acid on human blood
coagulation. Perfusion. 2018;33:577–83.
10. Gattas DJ, Rajbhandari D, Bradford C, Buhr H, Lo S, Bellomo R. A randomized
controlled trial of regional citrate versus regional heparin anticoagulation
for continuous renal replacement therapy in critically ill adults. Crit Care
Med. 2015;43:1622–9.
11. Carr JA, Silverman N. The heparin-protamine interaction: a review. J
Cardiovasc Surg. 1999;40:659–66.
Tramarin et al. Journal of Medical Case Reports          (2019) 13:123 Page 4 of 4
